Literature DB >> 16282893

Allogeneic bone marrow transplantation for chemotherapy-refractory hepatosplenic gammadelta T-cell lymphoma: case report and review of the literature.

Jennifer Ann Domm1, Maryann Thompson, John Frank Kuttesch, Sari Acra, Haydar Frangoul.   

Abstract

Hepatosplenic gammadelta T-cell lymphoma is an uncommon pediatric disease and is associated with an aggressive and often fatal course. The authors describe the case of an 8-year-old girl who presented with transaminitis and hepatosplenomegaly. Liver biopsy and peripheral blood flow cytometry were diagnostic of hepatosplenic gammadelta T-cell lymphoma. She was treated with multi-agent chemotherapy with cyclophosphamide, vincristine, prednisone, doxorubicin, and high-dose methotrexate but failed to achieve durable remission. She underwent an allogeneic bone marrow transplant from her HLA-identical brother with a preparative regimen including total body irradiation and cyclophosphamide. She is currently alive and has remained in remission for 30 months after transplantation. The authors also review the literature for similar pediatric cases.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16282893     DOI: 10.1097/01.mph.0000187431.37369.f5

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  7 in total

1.  IL-17 induces radiation resistance of B lymphoma cells by suppressing p53 expression and thereby inhibiting irradiation-triggered apoptosis.

Authors:  Qingshan Li; Xin Xu; Weijie Zhong; Qinghua Du; Bizhen Yu; Huabao Xiong
Journal:  Cell Mol Immunol       Date:  2014-12-29       Impact factor: 11.530

Review 2.  Hepatosplenic T-cell lymphoma: a rare but challenging entity.

Authors:  Barbara Pro; Pamela Allen; Amir Behdad
Journal:  Blood       Date:  2020-10-29       Impact factor: 22.113

3.  Intensive induction chemotherapy followed by early high-dose therapy and hematopoietic stem cell transplantation results in improved outcome for patients with hepatosplenic T-cell lymphoma: a single institution experience.

Authors:  Martin H Voss; Matthew A Lunning; Jocelyn C Maragulia; Esperanza B Papadopoulos; Jenna Goldberg; Andrew D Zelenetz; Steven M Horwitz
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2012-10-27

4.  Sustained first remission in an adolescent with hepatosplenic T-cell lymphoma treated with T-cell leukemia induction, nucleoside analog-based consolidation, and early hematopoietic stem cell transplant.

Authors:  Eric Schafer; Allen Chen; Robert J Arceci
Journal:  Pediatr Blood Cancer       Date:  2009-12       Impact factor: 3.167

5.  Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies.

Authors:  N K El-Mallawany; J K Frazer; P Van Vlierberghe; A A Ferrando; S Perkins; M Lim; Y Chu; M S Cairo
Journal:  Blood Cancer J       Date:  2012-04-13       Impact factor: 11.037

Review 6.  Biology and management of rare primary extranodal T-cell lymphomas.

Authors:  Mark Roschewski; Wyndham H Wilson
Journal:  Oncology (Williston Park)       Date:  2010-01       Impact factor: 2.533

7.  An Unusual Case of Hepatosplenic αβ T-Cell Lymphoma Presenting with Coombs'-Negative Hemolytic Anemia.

Authors:  Feryal A Ibrahim; Vignesh Shanmugam; Aliaa Amer; Halima El-Omri; Ahmad Al-Sabbagh; Ruba Y Taha; Dina S Soliman
Journal:  Clin Med Insights Oncol       Date:  2015-12-02
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.